Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database

  • Koeks, Zaïda
  • Bladen, Catherine L
  • Salgado, David
  • van Zwet, Erik
  • Pogoryelova, Oksana
  • McMacken, Grace
  • Monges, Soledad
  • Foncuberta, Maria E
  • Kekou, Kyriaki
  • Kosma, Konstantina
  • Dawkins, Hugh
  • Lamont, Leanne
  • Bellgard, Matthew I
  • Roy, Anna J
  • Chamova, Teodora
  • Guergueltcheva, Velina
  • Chan, Sophelia
  • Korngut, Lawrence
  • Campbell, Craig
  • Dai, Yi
  • Wang, Jen
  • Barišić, Nina
  • Brabec, Petr
  • Lähdetie, Jaana
  • Walter, Maggie C
  • Schreiber-Katz, Olivia
  • Karcagi, Veronika
  • Garami, Marta
  • Herczegfalvi, Agnes
  • Viswanathan, Venkatarman
  • Bayat, Farhad
  • Buccella, Filippo
  • Ferlini, Alessandra
  • Kimura, En
  • van den Bergen, Janneke C
  • Rodrigues, Miriam
  • Roxburgh, Richard
  • Lusakowska, Anna
  • Kostera-Pruszczyk, Anna
  • Santos, Rosário
  • Neagu, Elena
  • Artemieva, Svetlana
  • Rasic, Vedrana Milic
  • Vojinovic, Dina
  • Posada De la Paz, Manuel
  • Bloetzer, Clemens
  • Klein, Andrea
  • Díaz-Manera, Jordi
  • Gallardo, Eduard
  • Karaduman, A Ayşe
  • Oznur, Tunca
  • Topaloğlu, Haluk
  • El Sherif, Rasha
  • Stringer, Angela
  • Shatillo, Andriy V
  • Martin, Ann S
  • Peay, Holly L
  • Kirschner, Jan
  • Flanigan, Kevin M
  • Straub, Volker
  • Bushby, Kate
  • Béroud, Christophe
  • Verschuuren, Jan J
  • Lochmüller, Hanns
Background: Recent short-term clinical trials in patients with Duchenne Muscular Dystrophy (DMD) have indicated greater disease variability in terms of progression than expected. In addition, as average life-expectancy increases, reliable data is required on clinical progression in the older DMD population. Objective: To determine the effects of corticosteroids on major clinical outcomes of DMD in a large multinational cohort of genetically confirmed DMD patients. Methods: In this cross-sectional study we analysed clinical data from 5345 genetically confirmed DMD patients from 31 countries held within the TREAT-NMD global DMD database. For analysis patients were categorised by corticosteroid background and further stratified by age. Results: Loss of ambulation in non-steroid treated patients was 10 years and in corticosteroid treated patients 13 years old (p = 0.0001). Corticosteroid treated patients were less likely to need scoliosis surgery (p < 0.001) or ventilatory support (p < 0.001) and there was a mild cardioprotective effect of corticosteroids in the patient population aged 20 years and older (p = 0.0035). Patients with a single deletion of exon 45 showed an increased survival in contrast to other single exon deletions. Conclusions: This study provides data on clinical outcomes of DMD across many healthcare settings and including a sizeable cohort of older patients. Our data confirm the benefits of corticosteroid treatment on ambulation, need for scoliosis surgery, ventilation and, to a lesser extent, cardiomyopathy. This study underlines the importance of data collection via patient registries and the critical role of multi-centre collaboration in the rare disease field.
Repisalud
Publication Artículo científico (JournalArticle)

The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations

  • Bladen, Catherine L
  • Salgado, David
  • Monges, Soledad
  • Foncuberta, Maria E
  • Kekou, Kyriaki
  • Kosma, Konstantina
  • Dawkins, Hugh
  • Lamont, Leanne
  • Roy, Anna J
  • Chamova, Teodora
  • Guergueltcheva, Velina
  • Chan, Sophelia
  • Korngut, Lawrence
  • Campbell, Craig
  • Dai, Yi
  • Wang, Jen
  • Barišić, Nina
  • Brabec, Petr
  • Lähdetie, Jaana
  • Walter, Maggie C
  • Schreiber-Katz, Olivia
  • Karcagi, Veronika
  • Garami, Marta
  • Viswanathan, Venkatarman
  • Bayat, Farhad
  • Buccella, Filippo
  • Kimura, En
  • Koeks, Zaïda
  • van den Bergen, Janneke C
  • Rodrigues, Miriam
  • Roxburgh, Richard
  • Lusakowska, Anna
  • Kostera-Pruszczyk, Anna
  • Zimowski, Janusz
  • Santos, Rosário
  • Neagu, Elena
  • Artemieva, Svetlana
  • Rasic, Vedrana Milic
  • Vojinovic, Dina
  • Posada De la Paz, Manuel
  • Bloetzer, Clemens
  • Jeannet, Pierre-Yves
  • Joncourt, Franziska
  • Díaz-Manera, Jordi
  • Gallardo, Eduard
  • Karaduman, A Ayşe
  • Topaloğlu, Haluk
  • El Sherif, Rasha
  • Stringer, Angela
  • Shatillo, Andriy V
  • Martin, Ann S
  • Peay, Holly L
  • Bellgard, Matthew I
  • Kirschner, Jan
  • Flanigan, Kevin M
  • Straub, Volker
  • Bushby, Kate
  • Verschuuren, Jan
  • Aartsma-Rus, Annemieke
  • Béroud, Christophe
  • Lochmüller, Hanns
Analyzing the type and frequency of patient-specific mutations that give rise to Duchenne muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial planning, and improved clinical care. Locus-specific databases allow for the collection, organization, storage, and analysis of genetic variants of disease. Here, we describe the development and analysis of the TREAT-NMD DMD Global database (http://umd.be/TREAT_DMD/). We analyzed genetic data for 7,149 DMD mutations held within the database. A total of 5,682 large mutations were observed (80% of total mutations), of which 4,894 (86%) were deletions (1 exon or larger) and 784 (14%) were duplications (1 exon or larger). There were 1,445 small mutations (smaller than 1 exon, 20% of all mutations), of which 358 (25%) were small deletions and 132 (9%) small insertions and 199 (14%) affected the splice sites. Point mutations totalled 756 (52% of small mutations) with 726 (50%) nonsense mutations and 30 (2%) missense mutations. Finally, 22 (0.3%) mid-intronic mutations were observed. In addition, mutations were identified within the database that would potentially benefit from novel genetic therapies for DMD including stop codon read-through therapies (10% of total mutations) and exon skipping therapy (80% of deletions and 55% of total mutations).
Repisalud
Publication Artículo de revisión (ReviewArticle)

Current trends in biobanking for rare diseases: a review

  • Graham, Caroline E
  • Molster, Caron
  • Baynam, Gareth
  • Bushby, Kate
  • Hansson, Mats
  • Kole, Anna
  • Mora, Marina
  • Monaco, Lucia
  • Bellgard, Matthew I
  • Carpentieri, David
  • Posada De la Paz, Manuel
  • Riess, Olaf
  • Rubinstein, Yaffa R
  • Schaefer, Franz
  • Taruscio, Domenica
  • Terry, Sharon F
  • Zatloukal, Kurt
  • Knoppers, Bartha
  • Lochmüller, Hanns
  • Dawkins, Hugh
Rare diseases (RD) refer to a collection of approximately 5,000–8,000 individual diseases that have a low prevalence and are often genetic in origin. While RD can manifest throughout life, they frequently affect children and newborns. Common characteristics include being severe, disabling, life-threatening, degenerative and affecting different organ systems. The burden of RD is often exacerbated by a lack of specific treatments. Whilst there is etiological heterogeneity, there is overlap in cellular and molecular pathways. Amongst specialists, there is legitimate hope that based on genetic knowledge and pathway definition, a new medical classification system, currently called “precision medicine”, will be developed, which may change our view on how to apply shared therapeutic targets. Thus, collection of clinical and genetic data and biospecimens (in biobanks) will play an increasing role in diagnoses and development of therapies for RD. Biobanks are maintained collaboratively by researchers or their institutions, and involve a delicate balance between health policy objectives, academic research, public good outcomes, and community trust. Due to the nature of RD, international cooperation is critical for sharing limited numbers of RD samples and achieving a critical mass. Here we review the current and future direction of RD biobanks and discuss research and development stemming from the use of biospecimens to improve management of RD.